Research Report: Jardiance Reduces Cardiovascular Risk for Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly and Company announced their primary results for the EMPA-REG outcome trial. The study showed that Jardiance® (empagliflozin), significantly reduces  the risk  for cardiovascular death,  by 14% for patients living with  type 2 diabetes, who are at a  higher risk for a cardiovascular event.

Read the full article at:

Leave a Reply

Your email address will not be published. Required fields are marked *